Listing of Claims:

1-10. (Canceled)

11. (Previously Presented) A method of treating Alzheimer's disease in a mammalian subject, comprising administering to the subject a dosage of: (a) an immunogenic Aβ fragment effective to produce an immune response comprising antibodies against Aβ; and, (b) an adjuvant that augments the immune response to Aβ, thereby treating Alzheimer's disease.

12-13. (Canceled)

14. (Previously Presented) The method of claim 11, wherein said Aβ fragment induces an immune response directed against a neoepitope formed by amyloid deposits with respect to amyloid precursor protein (APP).

15-20. (Canceled)

21. (Previously Presented) The method of claim 11, wherein said adjuvant is selected from the group consisting of STIMULON QS-21, 3-De-O-acylated-monophosphoryl lipid A, and alum.

22. (Previously Presented) The method of claim 11, wherein said immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to Aβ.

23. (Previously Presented) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to Aβ.

24. (Previously Presented) The method of claim 11, wherein said immune response is characterized by a serum titer of the antibodies Aβ corresponding to greater than about four times higher than a serum titer of anti-Aβ antibodies measured in a pre-treatment control serum sample.

25. (Previously Presented) The method of claim 24, wherein said serum titer of the antibodies is measured at a serum dilution of about 1:100.

26-58. (Canceled)

59. (Previously Presented) A method of prophylaxis of Alzheimer's disease in a mammalian subject, comprising administering to the subject a dosage of: (a) an immunogenic Aβ fragment effective to produce an immune response comprising antibodies against Aβ and, (b) an adjuvant that augments the immune response to the Aβ, thereby effecting prophylaxis of Alzheimer's disease.

60. (Previously Presented) The method of claim 59, wherein said Aβ fragment induces an immune response directed against a neoepitope formed by amyloid deposits with respect to amyloid precursor protein (APP).

61-63. (Canceled)

64. (Previously Presented) The method of claim 59, wherein said adjuvant is selected from the group consisting of STIMULON QS-21, 3 De-O-acylated-monophosphoryl lipid A, and alum.

65. (Previously Presented) The method of claim 59, wherein said immune response is characterized by a serum titer of the anti-Aβ antibodies of at least 1:1000 with respect to Aβ.

66. (Previously Presented) The method of claim 65, wherein said serum titer of the antibodies is at least 1:5000 with respect to Aβ.

67. (Previously Presented) The method of claim 59, wherein said immune response is characterized by a serum titer of the anti-Aβ antibodies corresponding to greater than about four times higher than a serum titer of anti-Aβ antibodies measured in a pre-treatment control serum sample.

68. (Previously Presented) The method of claim 59, wherein said serum titer of the antibodies is measured at a serum dilution of about 1:100.

69. (Canceled)

70. (Previously Presented) The method of claim 11, wherein the subject has a known genetic risk of Alzheimer's disease.

71. (Previously Presented) The method of claim 59, wherein the subject has a known genetic risk of Alzheimer's disease.

72. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ1-3.

73. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ1-4.

74. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ1-5.

75. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ1-6.

76. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ1-7.

77. (Canceled)

78. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ1-10.

79. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ1-12.

80. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ13-28.

81. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ25-35.

82. (Previously Presented) The method of claim 11, wherein said Aβ fragment is Aβ33-42.

83. (Previously Presented) The method of claim 11, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

84. (Previously Presented) The method of claim 72, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

85. (Previously Presented) The method of claim 73, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

86. (Previously Presented) The method of claim 74, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

87. (Previously Presented) The method of claim 75, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

88. (Previously Presented) The method of claim 76, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

89. (Canceled)

90. (Previously Presented) The method of claim 78, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

91. (Previously Presented) The method of claim 79, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

92. (Previously Presented) The method of claim 80, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

93. (Previously Presented) The method of claim 81, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

94. (Previously Presented) The method of claim 82, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

95. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ1-3.

96. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ1-4.

97. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ1-5.

98. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ1-6.

99. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ1-7.

100. (Canceled)

101. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ1-10.

102. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ1-12.

103. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ13-28.

104. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ25-35.

105. (Previously Presented) The method of claim 59, wherein said Aβ fragment is Aβ33-42.

106. (Previously Presented) The method of claim 59, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

107. (Previously Presented) The method of claim 95, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

108. (Previously Presented) The method of claim 96, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

109. (Previously Presented) The method of claim 97, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

110. (Previously Presented) The method of claim 98, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

111. (Previously Presented) The method of claim 99, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

112. (Canceled)

113. (Previously Presented) The method of claim 101, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

114. (Previously Presented) The method of claim 102, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

115. (Previously Presented) The method of claim 103, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

116. (Previously Presented) The method of claim 104, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.

117. (Previously Presented) The method of claim 105, wherein said Aβ fragment is linked to a carrier molecule to form a conjugate.